Company: HCWB
Filing Date: 2025-11-18
Form Type: 8-K
Source: 0001193125-25-285325
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-11-18
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On November 18, 2025, HCW Biologics Inc. (the “ Company”) issued a press release announcing that the first patient was dosed in a Company-sponsored, multi-center Phase 1 clinical trial to evaluate the Company’s lead product candidate, HCW9302, in patients with an autoimmune disorder. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.